Comparing two strategies for preventing strokes in patients with atrial fibrillation.
The Rhythm Evaluation for Anticoagulation with Continuous Monitoring of Atrial Fibrillation Trial (REACT-AF)
['FUNDING_OTHER'] · NORTHWESTERN UNIVERSITY AT CHICAGO · NIH-10914248
This study is looking at two ways to help prevent strokes in people with atrial fibrillation: one method uses blood-thinning medication all the time, while the other uses a smartwatch to check for AF episodes and only gives the medication when needed, to lower the risk of bleeding.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHWESTERN UNIVERSITY AT CHICAGO (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-10914248 on ClinicalTrials.gov |
What this research studies
This research investigates two different approaches to prevent strokes in patients with atrial fibrillation (AF). One approach involves continuous use of direct oral anticoagulants (DOACs), while the other uses a smartwatch to monitor AF episodes and only administers DOACs when an AF episode lasting over an hour is detected. This method aims to reduce the risk of bleeding associated with long-term anticoagulation by only treating during periods of increased stroke risk. Patients will be monitored in a multicenter trial to evaluate the effectiveness and safety of these strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of paroxysmal or persistent atrial fibrillation and a low-to-moderate risk of stroke.
Not a fit: Patients with high stroke risk or those who do not have atrial fibrillation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safer and more effective way to prevent strokes in patients with atrial fibrillation.
How similar studies have performed: Previous research has shown promise in using technology for monitoring AF, but this specific approach of time-delimited DOAC treatment is novel.
Where this research is happening
CHICAGO, UNITED STATES
- NORTHWESTERN UNIVERSITY AT CHICAGO — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PASSMAN, ROD S — NORTHWESTERN UNIVERSITY AT CHICAGO
- Study coordinator: PASSMAN, ROD S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.